Hikma Pharmaceuticals (LSE:HIK) has scheduled a series of investor seminars devoted entirely to R&D, alongside a stated ambition to devote a larger share of Revenue to its pipeline. The question is how the generic and branded medicines group intends to use R&D to support growth, and what its recent results show about the Business that must fund it.

A multinational medicines maker

Hikma develops, manufactures and sells generic, specialty and branded medicines. Its half-year report divides the business into three segments: Injectables, which supplies hospital products; Hikma Rx, its US retail generics arm; and Branded, which sells mainly in the Middle East and North Africa. The company says it has manufactured in the United States for more than three decades and describes itself as one of the nation's largest suppliers of US-made generic medicines, with most production in Ohio and New Jersey. Said Darwazah is the chief executive. The shares are listed on the Main Market of the London Stock Exchange and on Nasdaq Dubai.

The R&D spotlight series

On 22 September 2026, Hikma announced three one-hour virtual seminars on its R&D strategy and capabilities. The first, on 20 October, covers group R&D together with respiratory, nasal, semi-solid and liquid products. The second, on 24 November, addresses solid oral medicines, and the third, on 16 December, focuses on injectables. The company said it aspires to invest "around 5% to 6% of revenue on R&D going forward", and stressed that "no new material financial or trading information will be provided" at the events.

Two days later, on 24 September, Hikma named Rebecca Hall, currently chief financial officer of ViiV Healthcare, as its next CFO from the first quarter of 2027. Khalid Nabilsi will leave the board on 31 December 2026 but remain Deputy CEO for North America and Europe.

What the half-year figures show

Hikma reported first-half revenue of $1,728 million on 6 August 2026, up 4% on a reported basis and 3% at constant currency. Core operating profit rose 9% to $405 million and core Earnings Per Share increased 5% to 128 cents. Branded was the standout, with revenue up 15% to $502 million and core operating profit of $163 million. Injectables revenue was flat at $685 million, while Hikma Rx slipped 1% to $520 million.

R&D spending rose 18% to $86 million, about 5% of revenue, and the company reported 48 product submissions, 40 approvals and 43 launches in the half. Net Debt was $1,694 million, or 1.9 times core EBITDA. The Interim Dividend rose 6% to 38 cents, and Hikma had bought back $227 million of shares under a $250 million programme. For 2026, it guided to constant currency revenue growth of 2% to 4% and core operating profit of $720 million to $770 million. By segment, it expects low single-digit revenue growth in Injectables, Branded growth at the top end of a 6% to 8% range and broadly flat Hikma Rx revenue.

Risks and points to watch

Generic medicines face persistent price erosion, especially in the US, and both Injectables and Hikma Rx were broadly flat in the half. Higher R&D spending will weigh on margins before new products contribute, and approval timelines are uncertain. US trade policy on pharmaceuticals remains a variable, although Hikma's domestic Manufacturing may provide some protection. A change of finance chief during 2027 planning adds a transition to manage.

Conclusion

Hikma is using its spotlight series to explain how it plans to raise R&D spending towards 5% to 6% of revenue, aiming to deepen a pipeline that already produced dozens of launches in the first half. The reported figures show growth driven largely by Branded, so the seminars may help show whether R&D can revive momentum in its US businesses.